Zabalafin hydrogel (AB-101a), a novel plant-based therapeutic, has shown promising interim results for treating atopic dermatitis (AD) in both pediatric and adult patients. A recent study highlights Zabalafin’s ability to rapidly reduce itch and improve quality of life. Managing Staphylococcus aureus on the skin is a core focus of the treatment, addressing a critical component of AD symptoms, including itch, inflammation, and infection-induced flare-ups. Interim data suggest the hydrogel is safe and effective for patients aged 2 years and older.

The study involved 10 participants—seven aged 3 to 17 years and three aged 18 to 45 years—who applied the hydrogel twice daily for eight weeks. By week 8, 80% of participants achieved an itch reduction score of 4 points or more from an initial severity of 8 out of 10. All participants reported improved quality of life, with Patient-Oriented Eczema Measure scores reduced by 6 points or more from a baseline score of 18.6 out of 28. These results emphasize Zabalafin’s potential for safe, long-term use. Researchers plan to initiate larger phase 2b trials in the United States and globally by early 2025.

Reference: Grasso G. Plant-based topical improves itch, quality of life among patients with atopic dermatitis. Healio. Published October 08, 2024. Accessed October 22, 2024. https://www.healio.com/news/dermatology/20241008/plantbased-topical-improves-itch-quality-of-life-among-patients-with-atopic-dermatitis?utm_source=selligent&utm_medium=email&utm_campaign=news|